Skip to main content

Dawn (Dan) Zhang is Co-Managing Shareholder of the Shanghai Office and Co-Chair of the firm's China Practice. She represents clients on international corporate transactions, in particular Asian clients on their investments, acquisitions, divestitures, and restructurings through Asia, Europe and the United States, and international companies’ business in Asia. She concentrates her practice on mergers and acquisitions, cross-border commercial transactions, international business, licensing, and general corporate and compliance matters, providing clients strategic as well as day-to-day legal advice. Further, Dawn advises clients on a wide range of industries, with particular emphasis on pharmaceuticals, medical devices, health care, automotive, retail, technology, oil and gas, manufacturing and hospitality. She is also experienced in assisting cross-border litigation, helping foreign companies in lawsuits filed in the United States.


  • Mergers and acquisitions, private equity and venture capital
  • Corporate governance and strategic advice
  • Life sciences
  • Pharmaceuticals, medical devices and life sciences, media, and information technology
  • Disputes resolutions
  • Asia Practice



  • Assisted LYFE Capital and Novo Holdings A/S regarding a $65 million three-tranche Series A-1 Preferred Stock investment round in iECURE, Inc., a Philadelphia-based gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need that spun-out from The University of Pennsylvania’s Gene Therapy Program.
  • Assisted PRA Health Sciences, a global clinical research organization, in forming a CRO joint venture with Wuxi PharmaTech to carry out Phase I-IV clinical trial services in China and handled the later separation of the joint venture.
  • Assist Lyfe Capital in selling equity in Brightech International, a leading CRO that specializes in complex, value-add biostatistics, programming and clinical data management services, to Everest Clinical Research, a full-service CRO with deep expertise in biostatistics and statistical programming.
  • Represented VcanBio Technologies, a Chinese publicly traded pharmaceutical company in connection with a $285 million acquisition of a U.S. gene technology and engineering company, including through a lengthy CFIUS approval process.
  • Represented Medtronic is divesting its subsidiary Beijing Libeier Bio-engineering Institute Co., Ltd. that manufactures and sells orthopedic implant products and associated instruments for trauma and spine indications to AK Medical Holdings Limited (SEHK:1789) at the price of US$40.2 million.
  • Assisted a global leader in business process and technology management in acquiring majority equity interest of a BPO service provider (under VIE structure) in Shanghai.
  • Assisted a consulting firm in selling their equity interest in a HK company and its Shanghai WFOE to a world leading consulting firm.
  • Acted as the primary lawyer in China to assist a leading OEM multinational corporation in acquiring a target company’s notebook PC OEM business for US$ 200 million.
  • Advised and assisted a leading U.S. automotive company in setting up in China an equity joint venture with a large PRC state-owned automotive company.
  • Represented the world’s largest contract manufacturer of wire formed medical devices and components in its strategic investment in a HK medical device company and its PRC subsidiaries.
  • Conducted in-depth due diligence and handled transactional documents for a research laboratory company with US$ 3 billion in annual sales for its US$ 30 million strategic investment in a PRC medical device group.
  • Represented a network infrastructure products and services provider in acquiring the equity interest of a PRC telecommunications equipment group for US$ 70 million.
  • Represented a leading NYSE-listed building products manufacturer in restructuring of its BVI and PRC subsidiaries, and in acquisition of a household appliance factory in Huizhou, China.
  • Assisted a digital operation platform for the life science industry from China to set up their business in the United States. The company independently develops a complete professional software product line, CRM and other SaaS products. Our legal work includes company establishment, personnel employment commercial contracts, consultation on immigration matters, office leasing, and development of privacy policies for websites and apps.
  • Assisted a cutting-edge technology company driven by computational design to set up a U.S. company to conduct business, including company establishment, employment contracts, website and app privacy policy development, etc.
  • Assisted a data and artificial intelligence high-tech company in setting up a U.S. company to conduct business. Our legal work includes the development of privacy policies for websites and apps.
  • Assisted a fund originating in China on investment in the United States, fund compliance, labor and employee disputes, etc.

Recognition & Leadership

  • Listed, Asian Legal Business, "Top 15 Rising Lawyers," 2014


  • LL.M., University of Pennsylvania Law School
  • LL.B., Fudan University School of Law
  • New York
  • Passed national PRC judicial qualification examination in 1998
  • Chinese (Mandarin), Fluent
  • English, Fluent